Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy

Radiotherapy and Oncology

Volumn 87, Issue 2, 2008, Pages 300-303

  Valeyrie Allanore, Laurence ^a   Poulalhon, Nicolas ^a   Fagot, Jean Paul ^a   Sekula, Peggy ^b   Davidovici, Batya ^c   Sidoroff, Alexis ^d   Mockenhaupt, Maja ^b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Amifostine; Radiotherapy; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONJUNCTIVITIS; CORNEA ULCER; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LARYNX CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION INJURY; SEPSIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AMIFOSTINE; EPIDERMAL NECROLYSIS, TOXIC; EUROPE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS; STEVENS-JOHNSON SYNDROME;

EID: 43049165955     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.01.021     Document Type: Article

References (20)

1. Mc Cauley D.L. Amifostine. A novel cytoprotective agent. Cancer Pract 5 (1997) 189-191
2. Lale Atahan I., Özyar E., Sahin S., Yildiz F., Yalcin F., and Karaduman A. Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy. Br J Dermatol 143 (2000) 1072-1073
3. Boccia R., Rani Anné P., Bourhis J., et al. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys 60 (2004) 302-309
4. Hicsonmez A., Andrieu M.N., Akyurek S., et al. In regard to Boccia et al.: assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol 61 (2005) 1279
5. Mockenhaupt M., Viboud C., Dunant A., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128 (2008) 35-44
6. Roujeau J.C., and Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 331 (1994) 1272-1285
7. Bastuji-Garin S., Rzany B., Stern R.S., Shear N.H., Naldi L., and Roujeau J.C. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 129 (1993) 92-96
8. Bastuji-Garin S., Fouchard N., Bertocchi M., Roujeau J.C., Revuz J., and Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115 (2000) 149-153
9. Capizzini R.L. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 123 (1996) 2-17
10. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000) 3339-3345
11. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractioned radiotherapy: a randomized phase II study. J Clin Oncol 18 (2000) 2226-2233
12. Ozsahin M., Betz M., Matzinger O., et al. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch Otolaryngol Head Neck Surg 132 (2006) 141-145
13. Anne P.R. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol 29 (2002) 80-83
14. Jellema A.P., Slotman B.J., Muller M.J., et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer 107 (2006) 544-553
15. Büntzel J., Glatzel M., Mücke R., Micke O., and Bruns F. Influence of amifostine onlate radiation-toxicity in head and neck cancer - a follow-up study. Anticancer Res 27 (2007) 1953-1956
16. Fagot J.P., Mockenhaupt M., Bouwes Bavinck J.N., Naldi L., Viboud C., and Roujeau J.C. EuroSCAR-study group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15 (2001) 1843-1848
17. Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1607
18. Fleischer Jr. A.B., Rosenthal D.I., Bernard S.A., and O'Keefe E.J. Skin reactions to radiotherapy - a spectrum resembling erythema multiforme: case report and review of the literature. Cutis 49 (1992) 35-39
19. Wöhrl S., Loewe R., Pickl W.F., Stingl G., and Wagner S.N. EMPACT syndrome. J Dtsch Dermatol Ges 3 (2005) 39-43
20. Mockenhaupt M., and Roujeau J.C. EMPACT syndrome. J Dtsch Dermatol Ges 3 (2005) 569-570